Prime Medicine Q1 2025 net loss $51.9M; cash $158.3M; pipeline on track for CGD data in 2025

Prime Medicine, Inc.

2025-Q1 EPS reported -$0.40 revenue$1,454,000

Net loss $51.9M (vs $45.8M Q1 2024); R&D $40.6M, G&A $13.3M.
Cash, equivalents, investments $158.3M as of March 31, 2025, down from $204.5M at Dec 31, 2024.
Initial Phase 1/2 data for PM359 (p47 phox CGD) expected in 2025.
IND/CTA for PM577 (Wilson's Disease) on track for 1H 2026; AATD program unveiled with IND/CTA mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.